B+
Bull case
25%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
CBIO
Crescent BiopharmaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Crescent has a funded oncology pipeline, ASCEND is already underway, CR-002 is targeting an IND in mid-2026, and management says cash should fund operations into 2028 after the $185 million private placement, giving it a real window to reach several clinical inflection points [#PR-2026-02-26].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -6.3.
What can break
Cash runway is stated into 2028, but sustained high R&D burn and a pre-revenue model still leave financing risk if timelines slip.
Momentum
76
Value
41
Sentiment
57
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $18.00 · Bull $30.00 · Bear $10.00Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $30.60
Why
Momentum76 · Δ7d +3.8
Value41 · Δ7d -0.0
Sentiment57 · Δ7d -6.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -6.3.
Contradictions & invalidation
- • Cash runway is stated into 2028, but sustained high R&D burn and a pre-revenue model still leave financing risk if timelines slip.
- • Clinical readouts are still ahead, so the stock remains highly exposed to trial-start and early-efficacy disappointment.
- • The company is still pre-proof-of-concept, losses are large, R&D spend ramped sharply in 2025, and most of the valuation depends on milestones and early data that are still well ahead; any enrollment, IND, or combination-trial delay could hit the stock hard [#PR-2026-02-26] [#10-K-2026-02-26].
Catalyst clock
2026-06-30
CR-002 IND submission target in mid-2026
Lead driver: Sentiment · See AI snapshot
Momentum
76
9% active weight
Current posture
7d trendSoftening
Δ7d
+3.8
Δ21d
+49.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
57
62% active weight
Current posture
7d trendSoftening
Δ7d
-6.3
Δ21d
-19.1
Why this grade
Composite grade C. Momentum 75.8 / Value 41.2 / Sentiment 56.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$649.28M
Beta
1.34
Shares Out
37.14M
P/E (TTM) · Derived
-1.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.19
Rev YoY
-100.0%
EPS YoY
-85.6%
Gross Margin
+98.2%
Op Margin
-422973.5%
Net Debt
-$211.55M
Current Ratio
9.66
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data